Label Changes for:
Capoten (Captopril Tablets, USP)
Changes have been made to the PRECAUTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
*The following was added:
- Dual blockade…RAS… Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors … other agents that block the RAS
- Do not co-administer Aliskiren with Capoten in patients with diabetes…